A closely watched treatment for Alzheimer’s disease came up short in a late-stage trial, marking the latest setback in a field wracked by years of failure. The drug, from biotech company TauRx, did no better than a sugar pill at improving patients’ scores on tests of cognitive and physical function, according to data presented early Wednesday…